Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program

I Posner, M Engel, A Gazit and A Levitzki

Department of Biological Chemistry, Hebrew University of Jerusalem, Israel.

The kinetics of inhibition of the epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase (TK) activity by erbstatin, tyrphostins, and lavendustin derivatives were studied in a system that employs poly(Glu6Ala3Tyr) (GAT) and ATP as substrates, after preactivation with EGF. All data were analyzed for computer best-fit curves by a program that was written for this purpose and is available upon request to those interested. The inhibition kinetics followed a sequential, Bi-Bi, rapid equilibrium, random mechanism, the mechanism of the EGFR-TK. Erbstatin and a few tyrphostins that contain a 3,4- dihydroxy-(cis)-cinnamonitrile [1-(3',4'-dihydroxyphenyl)-2- nitriloethene] group were found to be pure competitive inhibitors with respect to both substrates of the kinase reaction, i.e., GAT and ATP. Two tyrphostins, each containing an additional dihydroxyphenyl group in the alpha-position, were found to be pure competitive inhibitors with respect to GAT and noncompetitive (or mixed-competitive) inhibitors with respect to ATP. A lavendustin derivative with a 2,5- dihydroxyphenyl ring and a lavendustin derivative with a 3,4- dihydroyphenyl ring were also found to be competitive inhibitors with respect to both ATP and GAT. Various possible modes of binding at the EGFR-TK active center for the tyrphostins studied are proposed and the significance of the present findings, as well as the interpretations of computer analyses of kinetic data, is discussed.

Volume 45, Issue 4, pp. 673-683, 04/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				N. Y. Lee and J. G. Koland Conformational changes accompany phosphorylation of the epidermal growth factor receptor C-terminal domain Protein Sci., November 1, 2005; 14(11): 2793 - 2803. [Abstract] [Full Text] [PDF]

				G. A. Finlay, D. S. Hunter, C. L. Walker, K. E. Paulson, and B. L. Fanburg Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression Am J Physiol Cell Physiol, August 1, 2003; 285(2): C409 - C418. [Abstract] [Full Text] [PDF]

				T. C. Major and J. A. Keiser Inhibition of Cell Growth: Effects of the Tyrosine Kinase Inhibitor CGP 53716 J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 402 - 410. [Abstract] [Full Text]

				M. Parrizas, A. Gazit, A. Levitzki, E. Wertheimer, and D. LeRoith Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins Endocrinology, April 1, 1997; 138(4): 1427 - 1433. [Abstract] [Full Text] [PDF]

				A Levitzki and A Gazit Tyrosine kinase inhibition: an approach to drug development Science, March 24, 1995; 267(5205): 1782 - 1788. [Abstract] [PDF]